Posted by Michael Wonder on 16 Feb 2019
Alunbrig recommended by NICE for non-small-cell lung cancer
15 February 2019 - NICE has recommended the use of Alunbrig (brigatinib) for treating ALK-positive advanced non-small-cell lung cancer after Xalkori (crizotinib) on the NHS in England and Wales.
The decision comes after an earlier appraisal consultation document said the Takeda drug was not cost-effective in this setting.
An improved commercial agreement from the company and further clarifications about its economic model mean it is now recommended for routine use in the NHS.
